NMPA approves Lilly Elamine ® (Barretini tablets) 2mg tablets for the treatment of severe active rheumatoid arthritis in adults
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
rheumatoid arthritis is a chronic inflammatory autoimmune disease that seriously affects the daily work and life of patients, thus affecting their quality of lifeRecent epidemiological surveys show that the prevalence of rheumatoid arthritis in Chinese mainland is 0.28%, the total number of people with the disease is about 5 million, and the incidence rate of men and women is aboutrecently, Lilly China announced that the NationalDrug(http://Regulatory Authority (NMPA) approved the use of 2mg tablets of the Elamine ® (Barretini tablets) for the treatment of severe active rheumatoid arthritis in adultsEllamine ® (Barretinis tablets) is a tyrosine protein kinase (JAK) 1/2 inhibitor administered daily orallyElamine ® (Barretini tablets) is suitable for adult patients with moderate to severe active rheumatoid arthritis who have poor or intolerant efficacy in one or more anti-rheumatism drugs (DMARD) and may be used in combination with methotrexate or other abioticlyimproved anti-rheumatism drugs1The ® is developed by LillyPharmaceuticalhttp://and http://, the http://medicalSince its launch in 2017, the ® of Elmartin (Barretini tablets) has reached 50,000 patients in more than 60 countries worldwide, and looks forward to bringing treatment hope to more immunopathions in the future
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
